成人费城染色体阴性B细胞急性淋巴细胞白血病早期MRD阴性与生存的强烈预测关系
该研究分析215例接受强化化疗的初诊费城染色体阴性B细胞急性淋巴细胞白血病成人患者,在两个时间点用多色流式细胞术评估MRD;首次评估中位24天时148例(68%)MRD阴性,其中147例(99%)维持至第二次评估;两个时间点均MRD阴性者3年EFS和OS分别为65%和76%,优于由阳转阴者的42%和58%(P=.001)。
要点
- 首次评估中位24天时68%患者MRD阴性,其中99%维持至第二次评估。
- 两个时间点均MRD阴性者3年EFS 65%、OS 76%,优于由阳转阴者的42%和58%。
- 多因素分析显示KMT2A重排和首次评估MRD阳性是唯与较差OS相关的因素。
核心结论
- 早期实现MRD阴性缓解是成人费城染色体阴性B细胞急性淋巴细胞白血病更强的生存预后因素。
研究设计与样本
- 回顾性分析215例初诊费城染色体阴性B细胞急性淋巴细胞白血病成人患者,均接受强化化疗并在两个时间点有多色流式细胞术MRD评估。
- 首次评估(1TP)和第二次评估(2TP)的中位时间分别为24天和110天。
主要发现
- 1TP时148例(68%)MRD阴性,67例(32%)阳性;148例阴性者中147例(99%)维持至2TP。
- 两个时间点均MRD阴性(早期MRD应答者)的3年EFS和OS分别为65%和76%。
- MRD由阳性转为阴性(晚期MRD应答者)的3年EFS和OS分别为42%和58%(P=.001)。
- 多因素分析显示KMT2A(MLL)重排和1TP时MRD阳性是唯与较差OS相关的因素。
关键数值与推荐
- 1TP中位24天,2TP中位110天。
- 1TP MRD阴性率68%(148/215),阳性率32%(67/215)。
- 1TP阴性者中99%(147/148)维持至2TP阴性。
- 早期MRD应答者3年EFS 65%、OS 76%;晚期MRD应答者3年EFS 42%、OS 58%(P=.001)。
临床怎么用
- 在成人费城染色体阴性B细胞急性淋巴细胞白血病强化化疗中,应尽早(约24天)评估MRD。
- 早期MRD阴性且维持阴性提示生存预后较好,可由阳转阴者预后相对较差。
- KMT2A重排和早期MRD阳性提示OS较差,需加强风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The minimal or measurable residual disease (MRD) status following induction/consolidation chemotherapy is an important prognostic endpoint in adult patients with newly diagnosed acute lymphoblastic leukemia (ALL). However, the optimal time-point (TP) of MRD assessment and its impact on outcome remains unclear. We analyzed 215 patients with newly diagnosed Philadelphia negative B-cell ALL who received intensive chemotherapy, and had available MRD assessment by multicolor flow cytometry at two separate TPs. The median time to first TP (1TP) and second TP (2TP) were 24 and 110 days, respectively. At 1TP, 148 patients (68%) were MRD negative and 67 (32%) were positive. Of the 148 patients with negative MRD at 1TP, 147 (99%) maintained it through 2TP. Patients who were MRD negative at both TPs, early MRD responders, had the 3-year event-free survival (EFS), and overall survival (OS) rates of 65% and 76%, respectively. Patients with improved MRD status from positive to negative, late MRD responders, had lower 3-year EFS and OS rates, 42% and 58%, respectively (P = .001). Multivariate analysis showed that KMT2A (MLL) rearrangement and MRD positivity at 1TP were the only factors correlated with worse OS. In conclusion, the earlier achievement of MRD negative remission is a stronger prognostic factor for survival.
引用
- Yilmaz M, Kantarjian H, Wang X, et al. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2019. PMID: 31682008. doi:10.1002/ajh.25671
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。